[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606809":3},{"organization":4,"outcomesModule":7,"designInfo":36,"detailedDescription":35,"studyPopulation":35,"armGroups":42,"interventions":49,"overallOfficials":35,"centralContacts":35,"locations":54,"responsibleParty":162,"collaborators":35,"id":166,"slug":35,"hasResults":167,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":167,"sex":172,"minAge":173,"maxAge":35,"enrollmentInfo":174,"targetDuration":35,"studyType":177,"phases":178,"briefSummary":179,"conditions":180,"keywords":35,"overallStatus":57,"whyStopped":35,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":191},{"fullName":5,"class":6},"St. Antonius Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":19,"otherOutcomes":35},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Proportion clinically significant prostate cancer missed during follow up","Detection percentage of International Society of Urological Pathology Grade Group (ISUP GG)≥ 2 prostate cancer (= clinically significant prostate cancer) during 48 months of follow up compared with the percentage of total ISUP GG≥ 2 during the study, including any findings from end of study biopsies.\n\nISUP grade groups range from 1 to 5, and a ISUP GG≥ 2 is defined as clinically significant prostate cancer.","48 months",{"measure":14,"description":15,"timeFrame":12},"Number of clinically insignificant prostate cancer detected","Detection of clinically insignificant prostate cancer (International Society of Urological Pathology Grade Group (ISUP GG) 1) during the 48 months of follow up compared to the total ISUP GG 1 including end of study biopsies.",{"measure":17,"description":18,"timeFrame":12},"Number of negative biopsies","Number of participants with negative biopsy results during the study including findings from the end of study biopsies.",[20,23,26,29,32],{"measure":21,"description":22,"timeFrame":12},"Grade shifts","Progression rates of intermediate- to high-risk group during monitoring, rates of downgrading from intermediate risk to low risk",{"measure":24,"description":25,"timeFrame":12},"Detection of very high risk prostate cancer","Detection of very high risk prostate cancer (ISUP GG ≥ 3) during the study, including end of study biopsies.",{"measure":27,"description":28,"timeFrame":12},"Health-related quality of life (EPIC-26 score)","Change in health-related quality of life as measured by the Expanded Prostate Cancer Index Composite (EPIC-26), a validated questionnaire with subscales ranging from 0 to 100. Higher scores indicate better function and less symptom burden. Although the diagnosis of prostate cancer is not confirmed, this is the best validated and suitable questionnaire. Participants will be asked to fill in the questionnaire once a year.",{"measure":30,"description":31,"timeFrame":12},"Estimated average cost per patient during 48-month follow-up","Mean cost per participant over 48 months, including diagnostics (e.g. MRI, biopsies), consultations, and treatments, based on predefined unit costs and healthcare utilization.",{"measure":33,"description":34,"timeFrame":12},"Anxiety symptomes (STAI-6 score)","Change in anxiety levels as measured by the 6-item short form of the State-Trait Anxiety Inventory (STAI-6), with scores ranging from 20 to 80. Higher scores indicate greater anxiety. Participants will be asked to fill in the questionnaire once a year.",null,{"allocation":37,"interventionModel":38,"interventionModelDescription":35,"primaryPurpose":39,"observationalModel":35,"timePerspective":35,"maskingInfo":40},"NA","SINGLE_GROUP","DIAGNOSTIC",{"masking":41,"maskingDescription":35,"whoMasked":35},"NONE",[43],{"label":44,"type":45,"description":46,"interventionNames":47},"Study arm","EXPERIMENTAL","Participants will not undergo immediate prostate biopsy but will be monitored with PSA testing every six months and prostate MRI annually.",[48],"Other: PSA and MRI-monitoring",[50],{"type":6,"name":51,"description":52,"armGroupLabels":53,"otherNames":35},"PSA and MRI-monitoring","Men with PI-RADS 3 or 4 lesions and a PSA density ≤ 0.15 ng\u002FmL² are actively monitored with PSA testing every six months and MRI annually, instead of undergoing immediate prostate biopsy.",[44],[55,75,90,104,114,128,143],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Treant","RECRUITING","Emmen","Drenthe","7824AA","Netherlands","NL",{"type":64,"coordinates":65},"Point",[66,67],6.90694,52.77917,{"lat":67,"lon":66},[70],{"name":71,"role":72,"phone":73,"phoneExt":35,"email":74},"Luc A.J. Roelofs, MD, PhD","CONTACT","+310881290147","l.roelofs@treant.nl",{"facility":76,"status":57,"city":77,"state":78,"zip":79,"country":61,"countryCode":62,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Andros Clinics","Arnhem","Gelderland","6842 CV",{"type":64,"coordinates":81},[82,83],5.91111,51.98,{"lat":83,"lon":82},[86],{"name":87,"role":72,"phone":88,"phoneExt":35,"email":89},"Paul J.M. Kil, MD PhD","026 389 1753","p.kil@andros.nl",{"facility":91,"status":57,"city":92,"state":78,"zip":93,"country":61,"countryCode":62,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Radboud University Medical Centre","Nijmegen","6525 GA",{"type":64,"coordinates":95},[96,97],5.85278,51.8425,{"lat":97,"lon":96},[100],{"name":101,"role":72,"phone":102,"phoneExt":35,"email":103},"Toine G van der Heijden, MD PhD","024361 38 03","toine.vanderheijden@radboudumc.nl",{"facility":105,"status":57,"city":92,"state":78,"zip":35,"country":61,"countryCode":62,"cosmosGeoPoint":106,"geoPoint":108,"contacts":109},"Canisius Wilhelmina Hospital",{"type":64,"coordinates":107},[96,97],{"lat":97,"lon":96},[110],{"name":111,"role":72,"phone":112,"phoneExt":35,"email":113},"Rik M Somford, MD PhD","024 365 8255","r.somford@cwz.nl",{"facility":115,"status":57,"city":116,"state":117,"zip":35,"country":61,"countryCode":62,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Antoni van Leeuwenhoek Hospital","Amsterdam","North Holland",{"type":64,"coordinates":119},[120,121],4.88969,52.37403,{"lat":121,"lon":120},[124],{"name":125,"role":72,"phone":126,"phoneExt":35,"email":127},"Laura S Mertens, MD PhD","0205129111","l.mertens@nki.nl",{"facility":129,"status":130,"city":131,"state":132,"zip":35,"country":61,"countryCode":62,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"Maasstad Hospital","NOT_YET_RECRUITING","Rotterdam","South Holland",{"type":64,"coordinates":134},[135,136],4.47917,51.9225,{"lat":136,"lon":135},[139],{"name":140,"role":72,"phone":141,"phoneExt":35,"email":142},"Roderick C.N. van den Bergh, MD PhD","0102912265","BerghR@maasstadziekenhuis.nl",{"facility":144,"status":57,"city":145,"state":146,"zip":147,"country":61,"countryCode":62,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"St Antonius Hospital","Nieuwegein","Utrecht","3435 CM",{"type":64,"coordinates":149},[150,151],5.08056,52.02917,{"lat":151,"lon":150},[154,158],{"name":155,"role":72,"phone":156,"phoneExt":35,"email":157},"Vera Sweere, MD","0031612138028","v.sweere@antoniusziekenhuis.nl",{"name":159,"role":72,"phone":160,"phoneExt":35,"email":161},"Harm H.E. Van Melick, MD PhD","00316683201444","h.van.melick@antoniusziekenhuis.nl",{"type":163,"investigatorFullName":164,"investigatorTitle":165,"investigatorAffiliation":5,"oldNameTitle":35,"oldOrganization":35},"PRINCIPAL_INVESTIGATOR","Harm H.E. Van Melick","MD PhD","100606809",false,"NCT07180381","Sequential Imaging of Suspicion of Prostate Cancer Reducing Overdiagnosis and Unnecessary Biopsy With Timely Diagnosis of Significant Cancer","SPROUT","Inclusion Criteria:\n\n* Life expectancy \\> 10 years\n* initial PSA \\\u003C 20 ng\u002Fml\n* No signs of extracapsular disease on digital rectal examination\n* Intermediate-risk category for suspicion of prostate cancer determined by MRI results and PSA density (PSAD): PI-RADS 3 or PI-RADS 4 with PSAD =\\\u003C 0.15\n* Mentally competent and able to comprehend the potential benefits and burdens of the study\n* Willing to undergo the follow-up protocol for a maximum of four years\n* written and signed informed consent\n\nExclusion Criteria:\n\n* Men who have previously undergone a prostate biopsy\n* Men who have a prior PCa diagnosis\n* using any (anti-)hormonal therapy, including 5-alpha-reductase inhibitors\n* Proven germline mutation for PCa (for example: BRCA1; BRCA2)\n* Secondary malignancy, besides basal cell carcinoma of the skin, for which the potential participant is receiving active treatment at the time of inclusion.\n* severe claustrofobia or other conditions that make (repeat) MRI unsuitable (e.g., metal implants, pacemakers)","MALE","18 Years",{"count":175,"type":176},503,"ESTIMATED","INTERVENTIONAL",[37],"The goal of this clinical trial is to evaluate the safety and effectiveness of a novel diagnostic strategy for prostate cancer, in which men with a moderate risk of prostate cancer are monitored using PSA and MRI instead of immediate biopsy,.\n\nThe main questions it aims to answer are:\n\n* Is it safe to delay biopsy, making sure that clinical significant prostate cancers are not often missed?\n* Does it reduce unnecessary biopsies and overtreatment?",[181],"Prostate Cancer","2025-11-26",{"date":184,"type":185},"2025-12-04","ACTUAL",{"date":187,"type":185},"2025-05-14",{"date":189,"type":176},"2031-01",{"name":5,"class":6},7]